Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06105632 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | PHASE2 | ACTIVE NOT_RECRUITING | 333 | — | — | Jan 9, 2024 | Jan 21, 2028 | Feb 13, 2026 | 128 | United States, Argentina +12 |
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection) |
| Arm B | ACTIVE_COMPARATOR | Investigator's choice of therapy of either: * Fulvestrant alone (a solution for injection), or * Everolimus in combination with exemestane, both a tablet to be taken by mouth. |
| Name | Type | Description |
|---|---|---|
| PF-07220060 CDK4 inhibitor | DRUG | Experimental |
| Fulvestrant | DRUG | Experimental and Active comparator |
| Everolimus | DRUG | Active Comparator |
| Exemestane | DRUG | Active Comparator |
Inclusion Criteria: * Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Documented estrogen receptor (ER) and/or progesterone receptor (PR)- positive tumor * Do...